|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||0.5200 - 0.6200|
|52 Week Range||0.5200 - 0.6200|
|Beta (5Y Monthly)||4.22|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Mydecine Innovations Group Inc. Signs Definitive Agreement for Acquisition of NeuroPharm Inc. Positioned as a Leader in the Development of Psychedelic Treatments for the Betterment of Veterans
Dr. Reddy is one of the world's most pre-eminent authorities in applied microbiology as it relates to dairy foods, probiotics, and pollution mitigation. Nominated for the 2012 Nobel Peace Prize by the Chair of the United States Association of the state of Colorado , Dr. Reddy has received accolades and over 100 national and international awards and honors from all over the world.
Dr. Hoyer has been involved in drug discovery at leading pharmaceutical companies and research institutions for the last 30 years. Dr. Hoyer has unparalleled expertise in computational chemistry enabled probe molecule design, drug design and optimization, synthetic planning and execution, evaluation of chemical novelty and intellectual property assessment and strategies.
Whitefish, Montana--(Newsfile Corp. - June 24, 2020) - CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the leading media network dedicated to the global legal cannabis, CBD and psychedelics industries, today announces an article discussing psychedelic treatment, aftercare, and Mindleap Health's innovative approach to the practice.Image 1: Mindleap HealthTo view an enhanced version of Image 1, please visit:https://orders.newsfilecorp.com/files/6612/58428_8da51df83422581c_001full.jpgMillions of people have had a psychedelic experience at some point in their life ...
The advisory committee will review/monitor/access specific protocols and serve as an advocate for the organization providing technical expertise and collaborating with team members to help shape the direction of the various research programs. Vince Polito is a Research Fellow at Macquarie University and former Associate Investigator at the Australian Research Council Centre of Excellence in Cognition and its Disorders. Last year Mr. Polito conducted one of the largest to date Microdosing of psychedelics studies.
Mydecine Innovations Group Inc. (formerly New Leaf Brands Inc.) (CNSX: MYCO) (OTCMKTS: MYCOF) (FSE: 0NF) ("Mydecine" or the "Company") is pleased to announce that it has signed a definitive share exchange agreement with Mindleap Health Inc. ("Mindleap") for the acquisition of a 100% interest in MindLeap's Digital Telehealth Platform focused on the emerging psychedelics industry.